Press release content from PR Newswire. The AP news staff was not involved in its creation.
DarwinHealth Announces a Research Collaboration with Bristol Myers Squibb for a Novel Cancer Target Discovery (NCTI) Initiative
May 6, 2021 GMT
(PRNewsfoto/DarwinHealth)
NEW YORK, May 6, 2021 /PRNewswire/ DarwinHealth, a New York City-based biotechnology company, today announced a scientific research collaboration with Bristol-Myers Squibb Company (NYSE: BMY). The research collaboration, the Novel Cancer Target Initiative (NCTI), employs quantitative systems biology-based algorithms, proprietary databases, and validated technologies to identify novel cancer targets (NCTs) across a range of tumor subtypes.
The methodology underpinning the NCTI is based on an understanding of critical mechanisms linked to tumor dependencies and maintenance beyond genetic mutations. To facilitate the discovery of NCTs, DarwinHealth will provide Bristol Myers Squibb proprietary information residing in its d
DarwinHealth Scientists Publish Foundational Research Identifying Regulatory Mechanisms Controlling Cancer Cell States and Drug Response
News provided by
Share this article
Share this article
NEW YORK, Jan. 11, 2021 /PRNewswire/ DarwinHealth, Inc., a New York-based biotechnology and cancer drug discovery company announces the January 11, 2021 online publication in
Cell of a landmark paper, A Modular Master Regulator Landscape Controls Cancer Transcriptional Identity,
1,2 in which scientists from Columbia University and DarwinHealth apply the VIPER (Virtual Inference of Protein activity by Enriched Regulon) analysis algorithm to identify recurrent regulatory networks tumor checkpoints operative across the pancancer subtype continuum.
This research paper, with lead author Dr. Evan Paull, from the Department of Systems Biology at Columbia University, in conjunction with DarwinHealth Co-Founder, Professor Andrea Califano and Chief Scientific Officer, Dr. Mariano Alvarez a
12 gennaio 2021 07:40
Fonte: Adnkronos
#salute-e-benessere
NEW YORK, Jan. 11, 2021 /PRNewswire/ DarwinHealth, Inc., a New York-based biotechnology and cancer drug discovery company announces the January 11, 2021 online publication in Cell of a landmark paper, A Modular Master Regulator Landscape Controls Cancer Transcriptional Identity, 1,2 in which scientists from Columbia University and DarwinHealth apply the VIPER (Virtual Inference of Protein activity by Enriched Regulon) analysis algorithm to identify recurrent regulatory networks tumor checkpoints operative across the pancancer subtype continuum.
This research paper, with lead author Dr. Evan Paull, from the Department of Systems Biology at Columbia University, in conjunction with DarwinHealth Co-Founder, Professor Andrea Califano and Chief Scientific Officer, Dr. Mariano Alvarez and other investigators, presents results and analyses, using a novel Multi-Omics Master-Regulator Analysis framework (MOMA), that validate